

17 sites across globe

China



Shanghai Waigaoqiao
R D M



Shanghai Zhangjiang
R



Tianjin
R



Wuhan, Hubei
R



Chengdu, Sichuan
R



Qidong, Jiangsu
R



Shanghai Jinshan
D M



Changzhou, Jiangsu
D M



Changshu, Jiangsu
M



Taixing #1, Jiangsu
M



Taixing #2, Jiangsu
M



Wuxi city, Jiangsu
D M

United States



San Francisco, CA
R



San Diego, CA
D M



Middletown, DE
D M

Switzerland



Couvet, Neuchâtel
M

Singapore



Singapore
R D M

API R&D and manufacturing

4,199

Process Chemists & Analytical Scientists
as of Jan.31 2023

23

Plants

3023m³

Total Reactor Volume (TRV)

- Shanghai Waigaoqiao, China
- Shanghai Jinshan, China
- Changzhou, Jiangsu, China
- Taixing#2, Jiangsu, China
- Changshu, Jiangsu, China
- Tianjin, China
- Wuhan, Hubei, China
- San Diego, CA, USA

Drug Product R&D and manufacturing

1,470

Formulators and analytical scientists
as of Jan.31 2023

2,498

Molecules screened (2022)

45

Ongoing late phase and commercial projects

- Shanghai Waigaoqiao, China
- Wuxi City, China
- Couvet, Switzerland

Oligonucleotide and Peptide Platform



Shanghai
discovery oligo & peptide, preformulation & formulation development



Changzhou, Jiangsu
API process development & manufacturing



Taixing, Jiangsu
API process development & manufacturing (operational in 2023)



Wuxi city, Jiangsu
formulation development & manufacturing



Tianjin
discovery oligo, amidite, GalNAc



Wuhan, Hubei
discovery peptide



Chengdu, Sichuan
discovery peptide, unnatural amino acid



Middletown, DE
formulation development & manufacturing (operational in 2026)



Singapore
API process development & manufacturing (operational in 2026)

United States

China

Singapore

within 2-hour driving distance

O oligonucleotide P peptide

1,091 scientists

as of Jan.31st 2023